Sadatmansoori S, MacDougall J, Khademi S, Cooke L S, Guarino L, Meyer E F, Forough R
Department of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.
Protein Expr Purif. 2001 Dec;23(3):447-52. doi: 10.1006/prep.2001.1542.
We report DNA construction, baculovirus expression, and partial characterization of a minienzyme form of the human matrix metalloproteinase-9 (MMP-9). The MMP-9 minienzyme gene construct consisting of the pre, pro, and catalytic domains of the MMP-9 was introduced into Sf9 insect cells using a baculovirus expression system. The expression of the recombinant MMP-9 minienzyme was estimated to be approximately 0.8 mg/L of cell medium. The recombinant protein was purified using a single-step gelatin-Sepharose affinity column and yielded a highly stable and active minienzyme with gelatinolytic activity. Moreover, two interesting findings related to MMP-9 interactions with heparin and TIMP-1 resulted from our studies. First, the pro and catalytic domains of the human MMP-9 are not sufficient for heparin affinity. Second, in contrast to the prevailing consensus, TIMP-1 blockade of the enzymatic activity of MMP-9 does not require prior binding to the C-terminus of its MMP-9 protein substrate.
我们报告了人基质金属蛋白酶-9(MMP-9)微型酶形式的DNA构建、杆状病毒表达及部分特性分析。使用杆状病毒表达系统将由MMP-9的前体、前肽和催化结构域组成的MMP-9微型酶基因构建体导入Sf9昆虫细胞。重组MMP-9微型酶的表达量估计约为每升细胞培养基0.8毫克。重组蛋白通过一步法明胶-琼脂糖亲和柱纯化,得到具有明胶溶解活性的高度稳定且有活性的微型酶。此外,我们的研究还得出了两个与MMP-9与肝素和组织金属蛋白酶抑制剂-1(TIMP-1)相互作用相关的有趣发现。第一,人MMP-9的前肽和催化结构域不足以产生肝素亲和力。第二,与普遍共识相反,TIMP-1对MMP-9酶活性的阻断并不需要事先与MMP-9蛋白底物的C末端结合。